Disclosure of monthly exercise status for stock acquisition rights (with an exercise price adjustment clause). As of August 12, 2026, all issued stock acquisition rights have been exercised. For the target month, a total of 713,700 shares were issued, 7,137 stock acquisition rights were exercised (5.25% of the total issued), and unexercised remaining shares were 0.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4583","jir_company_name":"Kaioom Bioscience Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4583-20260813-01.pdf","jir_short_summary":"Disclosure of monthly exercise status for stock acquisition rights (with an exercise price adjustment clause). As of August 12, 2026, all issued stock acquisition rights have been exercised. For the target month, a total of 713,700 shares were issued, 7,137 stock acquisition rights were exercised (5.25% of the total issued), and unexercised remaining shares were 0.","jir_summary":"### Section Heading\nThis is a monthly notice of the exercise status and completion of exercise of stock acquisition rights (with exercise price adjustment clause). As of August 12, 2026, all issued stock acquisition rights have been exercised. For the target month, 713,700 shares were issued, 7,137 stock acquisition rights were exercised, and the exercise rate against the issued total was about 1.05%, with 0 shares remaining unexercised.\n\n### Section 2 Heading\nFor the exercise date details, on each date from August 3 to August 12, issued shares and exercise price are shown; there was no exercise on August 4, and other days saw multiple exercises. The total number of listed shares for the target month was 68,053,800 shares, the total issued ordinary shares was 81,150,000 shares, and treasury stock was 22,819 shares. This disclosure involves dynamic movements of treasury stock, so dilutive impact is expected to be limited.","jir_financial_highlights":"Number of shares issued during the target month: 713,700 shares\nNumber of stock acquisition rights exercised: 7,137 units\nNew stock (shares): Unknown","jir_category":"","jir_hashtags":"#KaioomBioscience, #StockAcquisitionRights, #TreasuryStock","jir_key_figures":"Number of shares issued during the target month: 713,700 shares\nNumber of stock acquisition rights exercised: 7,137 units\nUnexercised remaining shares: 0 shares","jir_meta_title":"Kaioom Bioscience \u2013 Notice of Exercise Completion for Stock Acquisition Rights | August 2026","jir_meta_description":"Announcement of the monthly exercise status and completion of exercise for Kaioom Bioscience's 23rd stock acquisition rights (with exercise price adjustment clause). Discloses the breakdown of issued shares, exercised counts, and unexercised remaining shares for August 2026.","jir_og_title":"Kaioom Bioscience \u2013 Notice of Exercise Completion for Stock Acquisition Rights | August 2026","jir_og_description":"Publication of all exercises for the 23rd stock acquisition rights. Provides details such as 713,700 issued shares, 7,137 exercised rights, and 0 unexercised shares for August.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59315,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-103167","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n